ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Breast Cancer
Endometrial Cancer
Ovarian Cancer
Adenocarcinoma

Prostate Cancer trials near Barcelona, CT, ESP:

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisi...

Enrolling
Prostatic Disease
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Drug: Gedatolisib
Drug: Darolutamide

Phase 1, Phase 2

Celcuity

Barcelona, Spain and 12 other locations

primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% ...

Active, not recruiting
Prostate Cancer
Drug: ADT
Drug: ODM-201

Phase 2

European Organisation for Research and Treatment of Cancer (EORTC)

Badalona, Spain and 11 other locations

Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to ...

Active, not recruiting
Metastatic Hormone-sensitive Prostate Cancer
Drug: ADT (androgen deprivation therapy)
Drug: Nivolumab 10 MG/ML

Phase 2, Phase 3

Spanish Oncology Genito-Urinary Group

Barcelona, Spain and 29 other locations

Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...

Enrolling
Prostate Cancer
Drug: Saruparib (AZD5305)
Drug: Darolutamide

Phase 1

AstraZeneca
AstraZeneca

Barcelona, Spain and 18 other locations

The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expa...

Enrolling
Hormone-refractory Prostate Cancer
Drug: AMX-500 (SAR446329)

Phase 1, Phase 2

Vir Biotechnology

Barcelona, Spain and 7 other locations

and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: abiraterone acetate
Drug: olaparib

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 131 other locations

Locations recently updated

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abira...

Enrolling
Prostate Cancer
Drug: AMG 509
Drug: Abiraterone

Phase 1

Amgen
Amgen

Barcelona, Catalonia, Spain and 54 other locations

with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials....

Enrolling
Prostate Cancer
Drug: AAA617

Phase 4

Novartis
Novartis

Barcelona, Catalunya, Spain and 53 other locations

with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm)....

Enrolling
Prostate Cancer
Drug: Saruparib
Drug: Abiraterone + Prednisolone/Prednisone

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 194 other locations

Locations recently updated

Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men wo ...

Enrolling
Metastatic Castration-Resistant Prostate Cancer
Drug: ABBV-969

Phase 1

AbbVie
AbbVie

Barcelona, Spain and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems